Full Press Release Details
Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference
Wash. (JUNE 5, 2025) - Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its broad-spectrum protease inhibitor CDI-988 will
be featured in an oral presentation at the 2025 Military Health System Research Symposium (MHSRS) being held August 4-7 in Kissimmee,
Fla. Cocrystal is developing CDI-988 as a norovirus prophylaxis and treatment. Sam Lee, PhD, the Company's President and co-CEO,
will discuss Phase 1 results during the Broad-Spectrum Anti-Viral Countermeasures breakout session on August 4, 2025.
am pleased to be discussing CDI-988 at this prestigious conference that showcases innovative antiviral agents to treat militarily relevant
pathogens," said Dr. Lee. "Norovirus is a leading cause of acute gastroenteritis worldwide for which there are no approved
antiviral agents or vaccines. Norovirus spreads rapidly through confined spaces such as in ships or other military settings, and can
inflict severe vomiting and diarrhea, posing a potential threat to operational effectiveness and a significant economic burden.
developed CDI-988 as a potential breakthrough for norovirus prophylaxis and treatment using our proprietary structure-based platform
technology. Unlike conventional antivirals, it targets the virus' core replication machinery, halting infection at early stages regardless
of viral strain or mutation," he added. "We believe CDI-988 could transform how norovirus outbreaks are prevented and treated."
was designed and developed as a broad-spectrum inhibitor to a highly conserved region in the active site of 3CL viral proteases. Based
on a novel mechanism of action and superior broad-spectrum antiviral activity, CDI-988 represents a compelling first-in-class oral treatment
for both noroviruses and coronaviruses. Cocrystal has completed a single-center, randomized, double-blind,
placebo-controlled Phase 1 study in healthy adults evaluating the safety, tolerability and pharmacokinetics of CDI-988, including a food
proprietary structural biology, along with its expertise in enzymology and medicinal chemistry, enable its development of novel antiviral
agents. The Company's platform provides a three-dimensional structure of inhibitor complexes at near-atomic resolution, providing
immediate insight to guide Structure Activity Relationships. This helps to identify novel binding sites and allows for a rapid turnaround
of structural information through highly automated X-ray data processing and refinement. The goal of this technology is to facilitate
the development of best-in-class antiviral therapies that have fast onset of action or shortened treatment time, are safe, well tolerated
and easy to administer; and are effective against all viral subtypes that cause disease and have a high barrier to viral resistance.
Military Health System Research Symposium
is an annual educational symposium with approximately 4,000 attendees that provides a collaborative environment for military medical
care providers with deployment experience, research and academic scientists, international partners and industry on research and related
healthcare initiatives falling under the topic areas of combat casualty care, military operational medicine, clinical and rehabilitative
medicine, information sciences, military infectious diseases and radiation health effects. More information is available here.
Cocrystal Pharma, Inc.
Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication
process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based
technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal,
please visit www.cocrystalpharma.com.
Note Regarding Forward-Looking Statements
press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including
statements regarding the potential efficacy of CDI-988 as a potential breakthrough for norovirus prophylaxis and treatment, and the potential
characteristics of and market for such product candidate and the Company's structure-based platform technology generally. The words
"believe," "may," "estimate," "continue," "anticipate," "intend," "should,"
"plan," "could," "target," "potential," "is likely," "will," "expect"
and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking
statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking
statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include,
but are not limited to, our need for additional capital to fund our operations over the next 12
months, risks relating to our ability to obtain regulatory approval for and proceed with
clinical trials including recruiting volunteers and procuring materials for such studies by our clinical research organizations and vendors,
the results of such studies, our and our collaboration partners' technology and software performing as expected, general risks
arising from clinical studies, receipt of regulatory approvals, regulatory changes, and potential development of effective treatments
and/or vaccines by competitors, potential mutations in a virus we are targeting that may result in variants that are resistant to a product
candidate we develop, the impact of the Trump Administration's policies and actions on regulation affecting the FDA and other healthcare
agencies and potential staffing issues resulting therefrom, as well as other government actions such as tariffs which may cause delays
or force us to incur additional costs to proceed without development programs. Further information on our risk factors is contained
in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2024. Any forward-looking statement
made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may
emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future developments or otherwise, except as may be required by law.